Federal Register #E2172023

NCI Offers Licensing and Research Partnerships for IL-12 Cell Therapy Platform and DNA Methylation Cancer Diagnostic

The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), is seeking partners for licensing and research co-development of two innovative biotechnology platforms: - Government Buyer: - National Institutes of Health (NIH) - Sub-agency: National Cancer Institute (NCI) - Office: Technology Transfer Center - Products/Technologies Offered: - Drug-Regulatable, Inducible Membrane-Bound Interleukin 12 (DRIM-IL-12) Platform - Part Number: E2172023 - Description: A tightly regulated, drug-responsive, membrane-bound IL-12 cytokine platform for adoptive cell therapy (ACT) with engineered T-cells (CAR, TCR, TILs) - Key Features: - IL-12 expression only upon T-cell activation - Drug-controlled safety switch to limit systemic toxicity - Demonstrated improved safety and efficacy in preclinical models - Patent filed (PCT/US2025/031121) - DNA Methylation-Based Cancer Diagnostic Platform - Description: Diagnostic tool using DNA methylation signatures for accurate tumor classification, especially for CNS, kidney, and hematopoietic tumors - Includes CNS classifier with 16,567 methylation profiles and 22 tumor families - Deployed as MethylScape Analysis software - Unique/Notable Requirements: - Seeking research co-development partners and/or licensees - Focus on advancing pre-clinical technologies toward clinical and commercial application - No specific product quantities or commercial OEMs named; technologies are at the pre-commercial stage - OEMs/Vendors: - No commercial OEMs or vendors are named; NCI/NIH is the technology originator

Description

Scientists at the National Cancer Institute (NCI) have developed a novel tightly regulated drug-responsive, membrane-bound IL-12 cytokine platform that enhances anti-tumor efficacy in adoptive cell therapy (ACT) with engineered T-cells (CAR, TCR, TILs) while improving safety. The NCI seeks research co-development partners and/or licensees to advance this technology toward clinical translation. This platform ensures IL-12 is expressed only upon T-cell activation and includes a drug-controlled safety switch to limit systemic toxicity. The technology is in the pre-clinical stage with demonstrated improved safety and efficacy in preclinical models.

View original listing